Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Documenti analoghi

• Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
  di: Sushrut S. Waikar, et al.
  Pubblicazione: (2025)
• Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
  di: Vaishali Sahasrabudhe, et al.
  Pubblicazione: (2025)
• Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
  di: Mark J. Ratain
  Pubblicazione: (2024)
• Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
  di: Yi‐An Bi, et al.
  Pubblicazione: (2024)
• Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
  di: Aarzoo Thakur, et al.
  Pubblicazione: (2024)